Date
- 2026 (30)
- 2025 (23)
- 2024 (40)
- 2023 (48)
- 2022 (26)
- 2021 (101)
- 2020 (61)
- 2019 (126)
- 2018 (40)
- 2017 (21)
- 2016 (22)
- 2015 (14)
- 2014 (22)
- 2013 (7)
- 2012 (3)
- 2010 (2)
- 2009 (10)
- 2008 (5)
- 2007 (11)
- 2006 (10)
- 2005 (12)
- 2004 (4)
- 2003 (2)
- 2002 (6)
- 2001 (3)
- 2000 (11)
- 1999 (5)
- 1998 (3)
- 1997 (1)
- 1996 (7)
- 1995 (2)
- 1994 (6)
- 1993 (5)
- 1991 (17)
Sponsor content
706 result(s) found, displaying 1 to 10
-
Australian Public Assessment Report (AusPAR)Cenrifki (tolebrutinib) is indicated in adults for the treatment of non-relapsing Secondary Progressive Multiple Sclerosis (nrSPMS) and to slow disability accumulation in the absence of relapse activity in adults with nrSPMS.
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for EPILIM SYRUP sodium valproate 40mg/mL oral liquid bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ALTUVIIIO efanesoctocog alfa 3000 IU powder for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ALTUVIIIO efanesoctocog alfa 500 IU powder for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ALTUVIIIO efanesoctocog alfa 4000 IU powder for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ALTUVIIIO efanesoctocog alfa 2000 IU powder for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ALTUVIIIO efanesoctocog alfa 1000 IU powder for injection vial.